Showing 2901-2910 of 3069 results for "".
- BioPharmX Reports Positive Topline Results of BPX-01 Topical Minocycline for Acnehttps://practicaldermatology.com/news/biopharmx-reports-positive-topline-results-of-bpx-01-topical-minocycline-for-acne/2458198/BioPharmX Corporation’s topical minocycline for acne, BPX-01, achieved its primary endpoint in a phase 2b clinical trial. There were statistically significant reductions in non-nodular inflammatory acne lesions when compared to vehicle in both the 1 percent and 2 percent doses of BP
- Allergan Officially Adds Coolsculpting to Portfoliohttps://practicaldermatology.com/news/allergan-adds-coolsculpting-to-portfolio/2458207/It’s a done deal. Allergan now owns ZELTIQ® Aesthetics. Allergan acquired ZELTIQ® Aesthetics for approximately $2.4 billion in cash. ZELTIQ® stockholders approved the transaction during its stockholder meeting h
- Kourtney Kardashian's Fave Skincare Brand Rolls Out New Body Oil Collectionhttps://practicaldermatology.com/news/kourtney-kardashians-fave-skincare-brand-rolls-out-new-body-oil-collection/2458212/Manuka Doctor is launching their newest body oil collection --The Manuka Doctor 24K Gold & Manuka Honey. The brand, which boasts Kourtney Kardashian as their global ambassador, is rolling out the new collection in late April 2017. The bo
- New Biomarker May Help Guide Metastatic Melanoma Treatment Decisionshttps://practicaldermatology.com/news/new-biomarker-may-guide-metastatic-melanoma-treatment-decisions/2458253/Measuring levels of Bim—a protein made by cancer-fighting T cells—via a simple blood draw can help doctors predict which metastatic melanoma patients would benefit from anti-PD-1 checkpoint blockade. Such personalized medicine can help eliminate some of the trial and error ass
- Cloudy With a Chance of Wrinkles: Most Americans Fail to Protect Skin From Pollutionhttps://practicaldermatology.com/news/cloudy-with-a-chance-of-wrinkles-most-americans-fail-to-protect-skin-from-pollution/2458275/Most Americans don’t protect their skin from pollutants even though they are aware of the harm that pollution and other environmental stressors can cause to skin, according to a new survey by H2O+ Beauty. Just 33 percent of people purchase
- Certain Lifestyle Choices May Trump Genes When it Comes to Youthful Looking Skinhttps://practicaldermatology.com/news/certain-lifestyle-choices-may-trump-genes-when-it-comes-to-youthful-looking-skin/2458313/Nurture has a larger effect on exceptionally youthful skin appearance than nature, according to a new study by Olay done in collaboration with personal genetics company 23andMe. Specifically, sunscreen usage and
- First Patient Treated in Dermata Therapeutics Phase 2 Acne Rosacea Clinical Studyhttps://practicaldermatology.com/news/first-patient-treated-in-dermata-therapeutics-phase-2-acne-rosacea-clinical-study/2458316/The first patient has been dosed in Dermata Therapeutics’s Phase 2 acne rosacea study of DMT210, a topical gel specifically developed to downregulate the proinflammatory cytokines in the skin responsible for the inflammation and redness seen in acne ro
- La Roche-Posay Debuts New Prebiotic Skincare Linehttps://practicaldermatology.com/news/la-roche-posay-debuts-new-prebiotic-skincare-line/2458323/La Roche-Posay is rolling out a new prebiotic Skincare Line. TOLERIANE Double Repair Moisturizer comes in a full line of products, including an SPF version and two complementary cleansers. The skin's microbiome is comprised of more than 100 b
- Revance Starts Phase III Program for Injectable Toxin in Frown Lineshttps://practicaldermatology.com/news/revance-starts-phase-iii-program-for-injectable-toxin-in-frown-lines/2458330/Revance Therapeutics began two double-blind, placebo-controlled, North American Phase III trials to evaluate single injections of DaxibotulinumtoxinA (RT002) for the treatment glabellar lines in about 600 total patients. These pivotal trials follo
- Enrollment Complete in BioPharmX's Phase 2b Study of Topical Minocycline Gel for Acnehttps://practicaldermatology.com/news/enrollment-complete-in-biopharmx-phase-2b-study-of-topical-minocycline-gel/2458331/BioPharmX Corporation completed enrollment in the OPAL (tOPicAL Minocycline Gel) study, a Phase 2b dose finding clinical trial to assess the efficacy and safety of BPX-01 for the treatment of acne vulgaris. The 12-week, multi-center, randomized, dou